[A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor]

Korean J Hepatol. 2006 Sep;12(3):449-54.
[Article in Korean]

Abstract

Overexpression of cyclooxygenase-2 (COX-2) has been associated with hepatocarcinogenesis. Inhibitors of COX-2 have proapoptotic and antiproliferative effects on malignant tumors and inhibit tumor invasion to the surrounding tissues. We report here a case of complete regression of advanced hepatocellular carcinoma (HCC) during COX-2 inhibitor administration. An eighty-year-old female was diagnosed as an advanced HCC, which was associated with HCV infection. She received COX-2 inhibitor for 3 months due to degenerative arthritis of both knees. Tumor enhancement on arterial phase CT completely disappeared without specific treatment for the HCC, and the tumor size decreased on the follow-up CT scan.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Celecoxib
  • Cyclooxygenase 2 Inhibitors / administration & dosage
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Diclofenac / administration & dosage
  • Diclofenac / analogs & derivatives
  • Diclofenac / therapeutic use
  • Female
  • Humans
  • Lactones / administration & dosage
  • Lactones / therapeutic use
  • Liver Neoplasms / drug therapy*
  • Pyrazoles / administration & dosage
  • Pyrazoles / therapeutic use
  • Sulfonamides / administration & dosage
  • Sulfonamides / therapeutic use
  • Sulfones / administration & dosage
  • Sulfones / therapeutic use

Substances

  • Cyclooxygenase 2 Inhibitors
  • Lactones
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • Diclofenac
  • Celecoxib
  • aceclofenac